Our Technology

Home - Randox Biosciences

Our Technology

 

Genomic Laboratory Technologies

Relatively new to the Randox Group is our Randox Genomics Services department, having been hugely successful in aiding the COVID testing programme, our established sequencing laboratory has been specifically designed and set up to fulfil a unique range of testing from our specialised laboratory in Northern Ireland.

Nucleic Acid Extraction and Isolation

Thermo Scientific KingFisher Flex

Automated nucleic acid extraction instruction that provides high throughput purification of up to 96 samples per run within 40 minutes.

Sample Quality Control

ThermoFisher Scientific Qubit 3.0 & Qubit Flex 

 

Capable of fast and specific nucleic acid quantification using fluorescence-based dye application, suitable for a lower throughput. More sensitive and accurate protocol than UV absorbance.

ThermoFisher Scientific Varioskan LUX 

 

Capable of rapid fluorescence-based UV absorbance nucleic acid analysis, suitable for high throughput of processing samples.

Agilent 4200 TapeStation System

 

An automated electrophoresis solution that with a scalable throughput (1-96 samples) can provide results in 1-2 minutes per plate with excellent reproducibility for sizing, concentration and integrity assessment.

Liquid Handling

Tecans 

 

Freedom EVO 150 base unit tecans, are automated liquid handling machines, enabling fully traceable, scalable (1-96 samples) automated library preparation including QC and library pooling.

Integra Viaflo 384

 

Viaflo 384 enables transfers of 24, 96 and 384 samples in a single step, thus increasing pipetting throughput and reproducibility significantly.

Integra Assist Plus

 

Pipette adapter: accommodates all Integra electronic multichannel pipettes- with fixed and adjustable tip spacing and the D-One single channel pipetting module.

Sequencing

Applied Biosystems SeqStudio Genetic Analyser 

 

Low-throughput benchtop system that delivers gold-standard Sanger sequencing technology and fragment analysis, easily used across a broad range of applications.

Next Generation Sequencing

MiSeq 

 

The MiSeq System is capable of automated paired-end reads and up to 15 Gb per run, delivering over 600 bases of sequence data per read.

NextSeq 2000

 

NextSeq 2000 System supports emerging and mid-throughput sequencing applications as well as a broad range of methods such as exome sequencing, target enrichment, single-cell profiling, transcriptome sequencing, and more. It offers an intuitive workflow with load-and-go ease and visual cues about run status. The NextSeq 2000 allows whole-exome sequencing of up to 48 samples in 33 hours.

NovaSeq6000

 

The most powerful sequencing instrument Illumina produce with the ability to provide scalable throughput for efficient whole-genome, whole exome and whole-transcriptome sequencing through sequencing by synthesis and patterned flow cell technology.

Genotyping

Illumina iScan

 

An innovative array scanner that supports rapid, sensitive, and accurate imaging of Illumina BeadChips for exceptional genetic analysis results. The iScan System can scan thousands of array samples per day, without sacrificing data quality or reproducibility. It supports an expansive portfolio of genetic analysis assays, from high-throughput genotyping to DNA methylation analysis.

Useful Resources

CDx & Biopharma Services


Next Generation Sequencing (NGS)

 

 

 

 

 

Next Generation Sequencing

Next-generation sequencing (NGS) is a sequencing technology that offers speed, scalability and ultra-high throughput. The technology can be used to determine the order of nucleotides in entire genomes or targeted regions of DNA or RNA. NGS has applications in environmental, agricultural and forensic science as well as genomic and clinical research.

NGS Workflow

Our Technology

Find Out More

NGS Capabilities

Whole Exome Sequencing (WES) is a wildly used NGS method that involves sequencing every protein coding region (approximately 21,000 genes) to identify any variants that may increase the risk of developing certain conditions or impact health/lifestyle. WES can be used across a broad range of applications including genetic disease, population genetics and cancer studies.

Advantages

  • Attains widespread coverage of coding regions
  • Cost effective alternative to Whole-Genome Sequencing (WGS)
  • Smaller data set provides faster and easy data analysis compared to WGS approaches

Human Whole Genome Sequencing (hWGS) involves sequencing very single base in your DNA (approximately 3.2 billion) to identify any variants that may increase the risk of developing certain conditions or impact health/lifestyle. This sequencing method has many applications including identifying genetic disorders, mutations responsible for cancer progression, as well as monitoring disease outbreaks.

 

Advantages

  • High-resolution view of the genome
  • Detection of all variant types
  • Low cost, fast library preparation

16s rRNA gene sequencing involves the analysis of the prokaryotic 16s ribosomal RNA gene which is found in all bacteria and archaea. This sequencing approach is extremely useful for microbiome research studies. 16s rRNA gene sequencing has a number of applications including, environmental, clinical and food

 

Advantages  

  • Identification and taxonomic classification of bacterial species
  • Fast speed and cost efficient
  • Discovery of novel pathogens

 

Shotgun sequencing reads all the genomic DNA in the sample, rather than just one specific region. This sequencing method provides a vast amount of genetic information as it can identify archaea, bacteria, fungi and viruses.

Advantages

  • Less labour intensive than other sequencing methods.
  • Faster process than clone-clone sequencing
  • Requires less DNA

 

qPCR

qPCR allows for the analysis of particular variants of specific locations. It is a good choice when interrogating  a small region of DNA on a limited number of samples. Real-time PCR can be used for both qualitative and quantitative analysis.

Advantages and Applications of qPCR 

  • Reactions are run, and data is evaluated in a unified, closed-tube qPCR system.
  • qPCR assays can be used to precisely monitor changes in gene expression.
  • Highly sensitive and reliable variant detection .
  • Quick and Simple Workflow
  • Primary equipment already available in most labs.

Next Generation Sequencing (NGS) Advantages

  • null

    High sample throughput

  • null

    High sensitivity

  • null

    Comprehensive genomic coverage

  • null

    Can sequence thousands of genes simultaneously

  • null
    Low sample input required
  • null

    Fast turnaround time for high sample volumes

Related Services

CDx & Biopharma Services


Genotyping Services

 

 

Genotyping Services

The Randox Genomics Services Department currently has target genotyping solutions in multiple areas. Genotyping is the process of analysing DNA to detect SNPs of interest. These SNPs are compared to reference SNPs, available from years of genetic research, to determine differences in genetic makeup.

Genotyping Advantages and Applications

Clinical Diagnostics

  • Can help determine whether specific resistance genes or genetic mutations in bacterial strains- make it insusceptible to one or more antibiotic drug.
  • Can be used to help monitor variants during pandemics, identifying when new variants become more predominant.

Clinical Research

  • Allows researchers to focus on genes, variants, and genomic regions of interest relevant to certain disease or traits of interest.
  • Enables the study of populations not supported by standard products and can be used to create personalised drugs.

Food & Agriculture

  • Identifies potential genes for improving breeding and management programs.
  • Can be used to increase yield and improve quality

Pharmacogenomics

Pharmacogenomics (PGx) is the study of how a person’s DNA effects their drug response. This is a relatively new field in science but it is expected to be the future of medicine as it focuses on personalised medicine and treating every patient individually.

Microarray Technology for PGx

At Randox we use Illumina’s Infinium Global Diversity Array with Enhanced PGx microarray to test for pharmacogenomic markers. This is the most comprehensive genotyping microarray on the market for pharmacogenomic research. The microarray features over 44,000 genome-wide PGx markers which span more than 20000 pharmacogenomic targets and gives 100% coverage of priority level A and B CPIC genes.

Genotyping Panels

  • null
    GSA + Custom content

    Over 710,000 SNPs across the human genome with additional DTC content.

  • null
    GDA + Enhanced PGx

    Over 1.8 million SNPs across the human genome enhanced with pharmacogenomic specific markers.

Laboratory Technology

Find Out More

Genotyping Workflow

Related Services

CDx & Biopharma Services


Genomics Services

 

 

Genomics Services

An End-to-End Genomics Solution

Randox Genomics Services department is fitted with specialised, fully equipped, state of the art testing facilities, designed and set up to fulfil a unique range of end-to-end sequencing solutions inclusive of in-house bioinformaticians and data analysts.

Why Randox?

Randox Laboratories is a global market leader within the in vitro diagnostics industry. Utilising a multitude of platforms, our sequencing and genotyping facility is suited to a wide range of areas of genome sequencing.

Our team of genetic scientists and bioinformaticians provide customisable sequencing and genotyping services for research, development, validation and running of different genomic tests to generate high quality data in line with modern healthcare and future disease insights.

  • null

    A dedicated team of genetic scientists including automation specialists, enabling adaption to testing throughputs changes from call small projects to large scale testing.

  • null

    Huge capacity for storage and accessioning of multiple sample types with fast turnaround times.

  • null

    Specific customised project planning and validation of services, tailored to the needs of each Randox customer.

  • null

    Multiple options for variable throughput from low throughput instruments, to the largest sequencer on the market with targeted solutions in multiple areas.

  • null
    Targeted genotyping solutions in multiple areas

Our Services

Genotyping

OLINK®

Related Services

CDx & Biopharma Services


OLINK

OLINK® | Comprehensive Biomarker Discovery

 

Let Experts at Randox Run Your Samples

As one of the UK’s first commercial partners of Olink® Proximity Extension Assay (PEA) technology, Randox offer scientists involved in drug development, clinical, or basic life science research, the service they need to run large-scale discovery proteomics.

 

Randox offer customers access to the entire Olink® protein library of ~3000 protein assays for exploratory proteomics and multiomics.

Olink® Technology- How it Works

Olink Proximity Extension Assay (PEA) technology offers a new method for measuring & detecting proteins of interest in a wide variety of sample types.

Using real-time PCR amplification, Olink platforms such as the Explore 3072 uses dual recognition with antibody- protein pairs in high multiplex to create 96 unique DNA reporter sequences. Using this approach, researchers can incorporate Olink’s kits into their workflow to measure and detect low abundance proteins whilst ensuring exceptional specificity and accuracy in serum or plasma samples.

The platform uses PEA technology combined with Next Generation Sequencing (NGS) readout methods to measure the relative concentration of proteins in liquid samples.

Workflow

Olink®- Driving the Future of Healthcare

Driven by precision medicine, the future of healthcare relies on a new generation of therapies to deliver the right treatment to the right patients at the right time. Proteomics is set to be at the forefront of this movement.

Technological limitations previously restricted comprehensive investigations of proteomics. Inhibiting large scale studies examining broad ranges of proteins in large numbers of human samples.

Olink® PEA technology provides an example as to how technological developments have eradicated past issues involving:

-Poor sensitivity

-Low throughput

-Large sample volume needed

-Lack of specificity

Features and Benefits

  • null
    Covers all major biological pathways with ~3000 validated protein assays
  • null
    High sample throughput for large scale proteomic studies and research
  • null
    Minimal sample volume with just 60uL for the complete library
  • null
    Exceptional specificity in comparison to mass spec utilising PEA technology
  • null
    Compatible with a wide variety of sample types

Randox Successfully Completed Olink® Concordance Testing

Randox successfully completed the Explore Concordance challenge as beta testers of the Concordance program, certifying the ability to operate the PEA with the same level of competency as the Olink® Analysis Service.

Randox Summary Report Acceptance Criteria Result
QC Warnings0%Max 16% allowed Passed the QC warning criteria
Detectability97.2%Min 85% allowed Passed the detectability criteria
Intra CV9%Max 15% allowedPassed the CV criteria
Median correlation coefficient (r)0.98Min 0.9 allowedPassed the correlation criteria.
Coefficient of determination (R2)0.96Min 0.9 allowedPassed the correlation criteria.
Overall, Randox passed all QC criteria, successfully passing the Olink Concordance Test on Explore 3072.
Download Full Report

Related Services

CDx & Biopharma Services


Randox Biosciences Resource Hub

Resource Hub | Biosciences

  • Brochures
  • Clinical Studies Group Publications
  • Flyers
  • Videos

Biosciences overview

Immunology

Molecular Testing

CDx & Biopharma Services

Cardiovascular & Metabolic

Acute Kidney Injury

2019.Stratifying risk of acute kidney injury in pre and post cardiac surgery patients using a novel biomarker-based algorithm and clinical risk score

Stratifying risk of acute kidney injury in pre and post cardiac surgery patients using a novel biomarker-based algorithm and clinical risk score - 2019

2021.Blood and urinary cytokine balance and renal outcomes at cardiac surgery

Blood and urinary cytokine balance and renal outcomes at cardiac surgery - 2021

2020.Acute kidney injury risk in orthopaedic trauma patients pre and post surgery using a biomarker algorithm and clinical risk score

Acute kidney injury risk in orthopaedic trauma patients pre- and post-surgery using a biomarker algorithm and clinical risk score - 2020

2020.Stratifying-Risk-of-Acute-Kidney-Injury-in-Pre-and-Post-Cardiac-Surgery-Patients-Using-a-Novel-Biomarker-Based-Algorithm-and-Clinical-Risk-Score

Stratifying Risk of Acute Kidney Injury in Pre- and Post-Cardiac Surgery Patients Using a Novel Biomarker Based Algorithm and Clinical Risk Score - 2020

ARID

2022.Plasma Soluble Tumor Necrosis Factor Receptor Concentrations and Clinical Events After Hospitalization- Findings From the ASSESS-AKI and ARID Studies

Plasma Soluble Tumor Necrosis Factor Receptor Concentrations and Clinical Events After Hospitalization- Findings From the ASSESS-AKI and ARID Studies - 2022

Diabetic Nephropathy

_2021_Harkin_On_tissue_chemical_derivatization_in_mass_spectrometry_imaging

On tissue chemical derivatization in mass spectrometry imaging - 2021

2022.Biomarkers for Detecting Kidney Dysfunction in Type-2 Diabetics and Diabetic Nephropathy Subjects A Case-Control Study to Identify Potential Biomar

Biomarkers for Detecting Kidney Dysfunction in Type-2 Diabetics and Diabetic Nephropathy Subjects A Case-Control Study to Identify Potential Biomarkers - 2022

2023.Analysis of reactive aldehydes in urine and plasma of type-2 diabetes mellitus patients through liquid chromatography-mass spectrometry Reactive al

Analysis of reactive aldehydes in urine and plasma of type-2 diabetes mellitus patients through liquid chromatography-mass spectrometry: Reactive aldehydes as potential markers of diabetic nephropathy - 2023

HABIO

2019.op68-value-engineered-translation-an-example-for-bladder-cancer-diagnosis

op68 value engineered translation an example for bladder cancer diagnosis - 2019

2020.Thrombomodulin Expression in Bladder Cancer Tissue and Its Association with Prognosis and Patient Survival

Thrombomodulin Expression in Bladder Cancer Tissue and Its Association with Prognosis and Patient Survival - 2020

2022.Biomarkers to assess the risk of bladder cancer in patients presenting with haematuria are gender-specific

Biomarkers to assess the risk of bladder cancer in patients presenting with haematuria are gender-specific - 2022

2024.Stratifying risk of disease in haematuria patients using machine learning techniques to improve diagnostics

Stratifying risk of disease in haematuria patients using machine learning techniques to improve diagnostics - 2024

HABIO Diabetes

2020.Stratifying-Risk-of-Acute-Kidney-Injury-in-Pre-and-Post-Cardiac-Surgery-Patients-Using-a-Novel-Biomarker-Based-Algorithm-and-Clinical-Risk-Score

Clinical features and predictive biomarkers for bladder cancer in patients with type 2 diabetes presenting with haematuria - 2022

MACE

2022.A novel algorithm for cardiovascular screening using conjunctival microcirculatory parameters and blood biomarkers.pdf

A novel algorithm for cardiovascular screening using conjunctival microcirculatory parameters and blood biomarkers - 2022

MAST4Health

2018. The 9th Santorini Conference- Systems Medicine

The 9th Santorini Conference: Systems Medicine, Personalised Health and Therapy. “The Odyssey from Hope to Practice”, Santorini, Greece, 30 September – 3 October 2018

2018.The polymorphism rs6918289 located in the downstream region of the TREM2 gene is associated with TNF-α levels and IMT-F

The polymorphism rs6918289 located in the downstream region of the TREM2 gene is associated with TNF-α levels and IMT-F - 2018

2019.Peripheral blood mononuclear cells extracts VEGFprotein levels and VEGF mRNA- Associations with inflammatory molecules in a healthy population

Peripheral blood mononuclear cells extracts VEGF protein levels and VEGF mRNA: Associations with inflammatory molecules in a healthy population - 2019

2020.Epigenome-wide association study in healthy individuals identifies significant associations with DNA methylation and PBMC extract VEGF-A concentration

Epigenome-wide association study in healthy individuals identifies significant associations with DNA methylation and PBMC extract VEGF-A concentration - 2020

2021.A genetic determinant of VEGF-A levels is associated with telomere attrition

A genetic determinant of VEGF-A levels is associated with telomere attrition - 2021

2021.Epigenome-wide association study detects a novel loci associated with central obesity in healthy subjects

Epigenome‑wide association study detects a novel loci associated with central obesity in healthy subjects - 2021

2021.Nutrigenetic Interactions Might Modulate the Antioxidant and AntiInflammatory Status in MastihaSupplemented Patients With NAFLD

Nutrigenetic Interactions Might Modulate the Antioxidant and Anti-inflammatory Status in Mastiha-Supplemented Patients With NAFLD - 2021

2022.Association of Dietary Patterns with MRI Markers of Hepatic Inflammation and Fibrosis in the MAST4HEALTH Study

Association of Dietary Patterns with MRI Markers of Hepatic Inflammation and Fibrosis in the MAST4HEALTH Study - 2022

2022.Epigenome-Wide Association Study (EWAS) of Blood Lipids in Healthy Population from STANISLAS Family Study (SFS)

Epigenome-Wide Association Study (EWAS) of Blood Lipids in Healthy Population from STANISLAS Family Study (SFS) - 2022

Myocardial Infarction

2018.diagnostic-performance-of-a-combination-biomarker-algorithm-for-ruleout-of-acute-myocardial-infarction-at-time-of-presentation-to-2155-9880-1000600

Diagnostic Performance of a Combination Biomarker Algorithm for Rule- Out of Acute Myocardial Infarction at Time of Presentation to the Emergency Department, Using Heart-Type Fatty Acid-Binding Protein and High-Sensitivity Troponin T tests - 2018

2019.AnAlgorithm Based on Combining hs-cTnT and H-FABP for Ruling Out Acute Myocardial Infarction

An Algorithm Based on Combining hs-cTnT and H-FABP for Ruling Out Acute Myocardial Infarction - 2019

NASH / NAFLD

2022.Non-alcoholic fatty liver disease—A pilot study investigating early inflammatory and fibrotic biomarkers of NAFLD with alcoholic liver disease

Non-alcoholic fatty liver disease—A pilot study investigating early inflammatory and fibrotic biomarkers of NAFLD with alcoholic liver disease - 2022

Polypharmacy

2019.THE INTENSITY AND IMPACT OF CHRONIC PAIN, A STORY OF DIFFICULTY SLEEPING AND POSTTRAUMATIC STRESS DISORDER

A review of the prescribing culture of anti-depressants across government districts in Northern Ireland - 2023

Post-Traumatic Stress Disorder

2019.THE INTENSITY AND IMPACT OF CHRONIC PAIN, A STORY OF DIFFICULTY SLEEPING AND POSTTRAUMATIC STRESS DISORDER

The Intensity and Impact of Chronic Pain, a Story of Difficulty Sleeping and Post-Traumatic Stress Disorder - 2019

2020.Sleep, a Governor of Morbidity in PTSD-A Systematic Review of Biological Markers in PTSDRelated Sleep Disturbances

Sleep, a Governor of Morbidity in PTSD: A Systematic Review of Biological Markers in PTSD-Related Sleep Disturbances - 2020

2021.Post-traumatic stress disorder- A biopsychosocial case-control study investigating peripheral blood protein biomarkers

Post-traumatic stress disorder: A biopsychosocial case-control study investigating peripheral blood protein biomarkers - 2021

2022.ABSTRACT.improving-sleep-in-a-population-at-high-risk-of-trauma-a-pilot-study-examining-self-reported-sleep-psychological-symptomology-and-actigraphy-measured-night-t

Improving sleep in a population at high risk of trauma: A pilot study examining self-reported sleep, psychological symptomology and actigraphy measured night-time sleep - 2022

2022.Post-traumatic stress disorder; identifying potential differences in participant response to CAPS-5 life events checklist questionnaire based on gender

Post-Traumatic Stress Disorder: Identifying Potential Differences in Participant Response to CAPS-5 Life Events Checklist Questionnaire Based on Gender - 2022

2023.Sleep Disturbances and Chronic Pain as Potential Indicators for Therapeutic Intervention in Subjects with Post-Traumatic Stress Disorder

Sleep Disturbances and Chronic Pain as Potential Indicators for Therapeutic Intervention in Subjects with Post-Traumatic Stress Disorder - 2023

2023. REVIEW. Post-Traumatic Stress Disorder- Sleep Disturbances and Biomarkers

Post-Traumatic Stress Disorder: Sleep Disturbances and Biomarkers - Review - 2023

Prostate Cancer

2019.ABSTRACT.McNAlly_et_al_diagnostic_classifiers_for_stratifying_patients_at_risk_of_prostate_cancer

Diagnostic classifiers for stratifying patients at risk of prostate cancer - 2019

2020.Biomarkers That Differentiate Benign Prostatic Hyperplasia from Prostate Cancer-A Literature Review

Biomarkers That Differentiate Benign Prostatic Hyperplasia from Prostate Cancer: A Literature Review - 2020

2022.A Novel Combination of Serum Markers in a Multivariate Model to Help Triage Patients Into “Low-” and “High-Risk” Categories for Prostate Cancer

A Novel Combination of Serum Markers in a Multivariate Model to Help Triage Patients Into “Low-” and “High-Risk” Categories for Prostate Cancer - 2022

Biosciences Bioreagents

Your Next Chosen Partner

Randox Bioreagents- Overview

Drug Induced Kidney Injury panel

Biochip Overview

Randox Multiplex Stroke Biochip

Biosciences Overview Video

Acute Kidney Injury

Randox Coronavirus Biochip Video

STI Campaign Video


Biosciences Overview

Randox Bioscience - Vivalytic Molecular Diagnostics

Biosciences

Your Next Trusted Partner

What we do.

As an established IVD company, Randox Biosciences offers tailored development and testing solutions to support faster, more effective and safe development of new therapeutics. We aim to advance scientific discovery, drug development & diagnostics.

 

From initial cultivation of raw materials for assay development, through to providing companion diagnostics, molecular and protein based custom assays across a range of therapeutic areas, we assist Pharma, Biotechs and CROs move away from a “one treatment fits all”  approach. Our aim is to advance the future of personalised medicine approaches to enable a better understanding of the complexity and variability of disease and increase efficacy of treatment.

We are your next trusted partner to achieve precise results, for faster drug approval through successful assay design, validation, registrations and co-commercialisation globally.

We are a world leading manufacturer of high -quality monoclonal and polyclonal antibody fragments and human recombinant proteins to assist diagnostic manufacturers. We also strive to assist clinical trials globally to reach their potential with the ability to provide multiplex technology, custom assay development, along with outsourcing solutions for testing.

Additionally, Randox Biosciences provides a wide range of assay formats including single nucleotide polymorphisms (SNP) genotyping, pathogen detection and mutation detection. Offering complete flexibility to achieve success in any collaborative partnership, assay development can be optimised for use on a wide range of third-party instruments and with the Randox Evidence Series – Biochip Technology platforms.

Our Expertise.

CDx & BioPharma Services

RCLS Testing

BioReagents

Resource Hub